NCT02729714View on ClinicalTrials.gov

A Pilot Study of Suvorexant for Insomnia in Parkinson Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

April 30, 2022

Study Completion Date

April 30, 2022

Conditions
Insomnia
Interventions
DRUG

Suvorexant

10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.

DRUG

Placebo

10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.

Trial Locations (1)

98034

Evergreenhealth Booth Gardner Parkinsons Care Center, Kirkland

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Burdick, Daniel, M.D.

INDIV

NCT02729714 - A Pilot Study of Suvorexant for Insomnia in Parkinson Disease | Biotech Hunter | Biotech Hunter